Technology transfer / Localization · CIS & Central Asia · Announced 22 Jan 2026
Nobel İlaç → Nobel Almaty Pharmaceutical Factory
Kazakhstan has approved a KZT 39.2bn localization project for Nobel İlaç's Almaty factory — 53 medicines plus APIs and biopharmaceuticals — deepening the Turkish group's two-decade manufacturing base in Central Asia.
Parties: Nobel İlaç (Turkey) → Nobel Almaty Pharmaceutical Factory JSC (Kazakhstan)
- Deal type
- Technology transfer / Localization
- Value
- $84m
- Territory
- Kazakhstan
- Therapeutic area
- Multi-therapy
- Asset
- Expanded GMP production in Almaty: 53 medicines (17 socially significant), plus active pharmaceutical ingredients and biopharmaceuticals
- Announced
- 22 Jan 2026
Our analysis
Why this matters
Kazakhstan's government has approved an investment agreement with Nobel Almaty Pharmaceutical Factory JSC, the Kazakh manufacturing arm of Türkiye's Nobel İlaç, for KZT 39.2 billion. The project covers 53 medicines, 17 of them socially significant, plus active pharmaceutical ingredients and biopharmaceuticals, built to GMP standards, and is expected to create more than 200 jobs.
Nobel has operated its Almaty factory since 2002 and exports from it to several countries, including Russia. Adding API and biopharmaceutical production moves the site up the value chain from finished generics, which is what Kazakhstan's localization policy is designed to reward.
The full analysis is free to read with a work email on this page.